Tom A BÃ¤ck

List of Publications by Year
in descending order

38 papers	1,476 citations	304743 22 h-index	315739 38 g-index
38 all docs	38 docs citations	38 times ranked	1011 citing authors

#	Article	IF	Citations
1	Intraperitoneal Î±-Particle Radioimmunotherapy of Ovarian Cancer Patients: Pharmacokinetics and Dosimetry of ²¹¹At-MX35 F(abâ€²)₂â€”A Phase I Study. Journal of Nuclear Medicine, 2009, 50, 1153-1160.	5.0	245
2	Dry-distillation of astatine-211 from irradiated bismuth targets: a time-saving procedure with high recovery yields. Applied Radiation and Isotopes, 2001, 55, 157-160.	1.5	124
3	The Î±-Camera: A Quantitative Digital Autoradiography Technique Using a Charge-Coupled Device for Ex Vivo High-Resolution Bioimaging of Î±-Particles. Journal of Nuclear Medicine, 2010, 51, 1616-1623.	5.0	97
4	Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease. Blood, 2010, 116, 4231-4239.	1.4	63
5	Direct Procedure for the Production of²¹¹At-Labeled Antibodies with an Îµ-Lysyl-3-(Trimethylstannyl)Benzamide Immunoconjugate. Journal of Nuclear Medicine, 2008, 49, 1537-1545.	5.0	60
6	Anti-CD45 radioimmunotherapy using 211At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model. Blood, 2013, 121, 3759-3767.	1.4	59
7	Intraperitoneal Î±-Emitting Radioimmunotherapy with ²¹¹At in Relapsed Ovarian Cancer: Long-Term Follow-up with Individual Absorbed Dose Estimations. Journal of Nuclear Medicine, 2019, 60, 1073-1079.	5.0	53
8	Astatine-211 conjugated to an anti-CD20 monoclonal antibody eradicates disseminated B-cell lymphoma in a mouse model. Blood, 2015, 125, 2111-2119.	1.4	52
9	Therapeutic efficacy and tumor dose estimations in radioimmunotherapy of intraperitoneally growing OVCAR-3 cells in nude mice with (211)At-labeled monoclonal antibody MX35. Journal of Nuclear Medicine, 2005, 46, 1907-15.	5.0	49
10	Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model. Blood, 2011, 118, 703-711.	1.4	48
11	Absorbed Doses and Risk Estimates of 211At-MX35 F(ab')2 in Intraperitoneal Therapy of Ovarian Cancer Patients. International Journal of Radiation Oncology Biology Physics, 2015, 93, 569-576.	0.8	45
12	Alpha-radioimmunotherapy of intraperitoneally growing OVCAR-3 tumors of variable dimensions: Outcome related to measured tumor size and mean absorbed dose. Journal of Nuclear Medicine, 2006, 47, 1342-50.	5.0	43
13	Labeling of Anti-HER2 Nanobodies with Astatine-211: Optimization and the Effect of Different Coupling Reagents on Their in Vivo Behavior. Molecular Pharmaceutics, 2019, 16, 3524-3533.	4.6	42
14	Realizing Clinical Trials with Astatine-211: The Chemistry Infrastructure. Cancer Biotherapy and Radiopharmaceuticals, 2020, 35, 425-436.	1.0	41
15	Pharmacokinetics, microscale distribution, and dosimetry of alpha-emitter-labeled anti-PD-L1 antibodies in an immune competent transgenic breast cancer model. EJNMMI Research, 2017, 7, 57.	2.5	35
16	Dose-Dependent Growth Delay of Breast Cancer Xenografts in the Bone Marrow of Mice Treated with²²³Ra: The Role of Bystander Effects and Their Potential for Therapy. Journal of Nuclear Medicine, 2020, 61, 89-95.	5.0	34
17	Comparison of therapeutic efficacy and biodistribution of 213Bi- and 211At-labeled monoclonal antibody MX35 in an ovarian cancer model. Nuclear Medicine and Biology, 2012, 39, 15-22.	0.6	32
18	Immunohistochemical evaluation of epithelial ovarian carcinomas identifies three different expression patterns of the MX35 antigen, NaPi2b. BMC Cancer, 2017, 17, 303.	2.6	30

#	Article	IF	Citations
19	Glomerular Filtration Rate After Alpha-Radioimmunotherapy with²¹¹At-MX35-F(abâ€²)₂: A Long-Term Study of Renal Function in Nude Mice. Cancer Biotherapy and Radiopharmaceuticals, 2009, 24, 649-658.	1.0	29
20	Automated astatination of biomolecules â€“ a stepping stone towards multicenter clinical trials. Scientific Reports, 2015, 5, 12025.	3.3	29
21	211At radioimmunotherapy of subcutaneous human ovarian cancer xenografts: evaluation of relative biologic effectiveness of an alpha-emitter in vivo. Journal of Nuclear Medicine, 2005, 46, 2061-7.	5.0	29
22	Ex Vivo Activity Quantification in Micrometastases at the Cellular Scale Using the Î±-Camera Technique. Journal of Nuclear Medicine, 2013, 54, 1347-1353.	5.0	24
23	Comparison of ²¹¹At-PRIT and ²¹¹At-RIT of Ovarian Microtumors in a Nude Mouse Model. Cancer Biotherapy and Radiopharmaceuticals, 2013, 28, 108-114.	1.0	21
24	Synthesis and Evaluation of Astatinated N-[2-(Maleimido)ethyl]-3-(trimethylstannyl)benzamide Immunoconjugates. Bioconjugate Chemistry, 2016, 27, 688-697.	3.6	20
25	Binding Affinity, Specificity and Comparative Biodistribution of the Parental Murine Monoclonal Antibody MX35 (Anti-NaPi2b) and Its Humanized Version Rebmab200. PLoS ONE, 2015, 10, e0126298.	2.5	19
26	Î±-Imaging Confirmed Efficient Targeting of CD45-Positive Cells After ²¹¹At-Radioimmunotherapy for Hematopoietic Cell Transplantation. Journal of Nuclear Medicine, 2015, 56, 1766-1773.	5.0	18
27	Biokinetic Modeling and Dosimetry for Optimizing Intraperitoneal Radioimmunotherapy of Ovarian Cancer Microtumors. Journal of Nuclear Medicine, 2016, 57, 594-600.	5.0	18
28	Cure of Human Ovarian Carcinoma Solid Xenografts by Fractionated Î±-Radioimmunotherapy with ²¹¹At-MX35-F(abâ€²)₂: Influence of Absorbed Tumor Dose and Effect on Long-Term Survival. Journal of Nuclear Medicine, 2017, 58, 598-604.	5.0	16
29	Targeted alpha therapy with astatine-211-labeled anti-PSCA A11 minibody shows antitumor efficacy in prostate cancer xenografts and bone microtumors. EJNMMI Research, 2020, 10, 10.	2.5	16
30	Therapeutic efficacy of Î±-radioimmunotherapy with different activity levels of the 213Bi-labeled monoclonal antibody MX35 in an ovarian cancer model. EJNMMI Research, 2017, 7, 38.	2.5	15
31	Evaluation of Effects on the Peritoneum After Intraperitoneal Î±-Radioimmunotherapy with²¹¹At. Cancer Biotherapy and Radiopharmaceuticals, 2012, 27, 353-364.	1.0	13
32	Radium-223â€“Induced Bystander Effects Cause DNA Damage and Apoptosis in Disseminated Tumor Cells in Bone Marrow. Molecular Cancer Research, 2021, 19, 1739-1750.	3.4	13
33	In Vivo Distribution of Avidin-Conjugated MX35 and 211At-Labeled, Biotinylated Poly-l-Lysine for Pretargeted Intraperitoneal Î±-Radioimmunotherapy. Cancer Biotherapy and Radiopharmaceuticals, 2011, 26, 727-736.	1.0	10
34	Evaluation of therapeutic efficacy of 211At-labeled farletuzumab in an intraperitoneal mouse model of disseminated ovarian cancer. Translational Oncology, 2021, 14, 100873.	3.7	9
35	Model of Intraperitoneal Targeted Î±-Particle Therapy Shows That Posttherapy Cold-Antibody Boost Enhances Microtumor Radiation Dose and Treatable Tumor Sizes. Journal of Nuclear Medicine, 2018, 59, 646-651.	5.0	8
36	Alpha particle induced DNA damage and repair in normal cultured thyrocytes of different proliferation status. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2014, 765, 48-56.	1.0	7

#	Article	IF	Citations
37	Modeling bystander effects that cause growth delay of breast cancer xenografts in bone marrow of mice treated with radium-223. International Journal of Radiation Biology, 2021, 97, 1217-1228.	1.8	6
38	Surface Adsorption of the Alpha-Emitter Astatine-211 to Gold Nanoparticles Is Stable In Vivo and Potentially Useful in Radionuclide Therapy. Journal of Nanotheranostics, 2021, 2, 196-207.	3.1	4